• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Pediatric fluoride prescriptions fall across the US

Pediatric fluoride prescriptions fall across the US

by Truveta Research | Jul 23, 2025 | Research, Research Insights

The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025 (2.3 per 1,000 prescriptions). Across the study period, the 10 US states with lowest...
Shifting trends in initiation of disease-modifying therapies for multiple sclerosis

Shifting trends in initiation of disease-modifying therapies for multiple sclerosis

by Truveta Research | Jul 16, 2025 | Research, Research Insights

The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

by Truveta Research | Jul 14, 2025 | Research, Research Insights

In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of medications for weight management in adolescents and cautioning against the common practice...
Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines

Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines

by Truveta Research | Jun 26, 2025 | Research, Research Insights

Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Biosimilar use is on the rise – but 1 in 8 patients return to Humira

by Truveta Research | Jun 23, 2025 | Research, Research Insights

Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization

New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization

by Truveta Research | Jun 13, 2025 | Research, Research Insights

Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
« Older Entries

Share this


Recent posts

  • GLP-1 RA prescription trends: January 2018 – June 2025
  • Pediatric fluoride prescriptions fall across the US
  • Truveta Experts: Real-world trends in Rituxan biosimilar adoption

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.